Limit this search to....

Gene Therapy for Cancer
Contributor(s): Hunt, Kelly K. (Editor), Vorburger, Stephan A. (Editor), Swisher, Stephen G. (Editor)
ISBN: 161737590X     ISBN-13: 9781617375903
Publisher: Humana
OUR PRICE:   $237.49  
Product Type: Paperback - Other Formats
Published: December 2010
Qty:
Temporarily out of stock - Will ship within 2 to 5 weeks
Additional Information
BISAC Categories:
- Medical | Oncology - General
- Medical | Hematology
- Medical | Forensic Medicine
Dewey: 614.599
Series: Cancer Drug Discovery & Development
Physical Information: 0.97" H x 7.01" W x 10" (2.44 lbs) 469 pages
 
Descriptions, Reviews, Etc.
Publisher Description:
The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.